These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 17671215)

  • 21. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
    Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
    Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
    Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].
    Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
    Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
    Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
    Mattarollo SR; Kenna T; Nieda M; Nicol AJ
    Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
    Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
    J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
    Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
    Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells
    Wang S; Li H; Ye C; Lin P; Li B; Zhang W; Sun L; Wang Z; Xue D; Teng W; Zhou X; Lin N; Ye Z
    Front Immunol; 2018; 9():377. PubMed ID: 29535738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism.
    Duault C; Franchini DM; Familliades J; Cayrol C; Roga S; Girard JP; Fournié JJ; Poupot M
    J Immunol; 2016 Jan; 196(1):493-502. PubMed ID: 26608919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
    Li Z; Peng H; Xu Q; Ye Z
    J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.
    Santini D; Martini F; Fratto ME; Galluzzo S; Vincenzi B; Agrati C; Turchi F; Piacentini P; Rocci L; Manavalan JS; Tonini G; Poccia F
    Cancer Immunol Immunother; 2009 Jan; 58(1):31-8. PubMed ID: 18458903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of γδ T cells.
    Takimoto R; Suzawa T; Yamada A; Sasa K; Miyamoto Y; Yoshimura K; Sasama Y; Tanaka M; Kinoshita M; Ikezaki K; Ichikawa M; Yamamoto M; Shirota T; Kamijo R
    Immunology; 2021 Mar; 162(3):306-313. PubMed ID: 33131052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
    Fiore F; Castella B; Nuschak B; Bertieri R; Mariani S; Bruno B; Pantaleoni F; Foglietta M; Boccadoro M; Massaia M
    Blood; 2007 Aug; 110(3):921-7. PubMed ID: 17403919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.
    Welton JL; Morgan MP; Martí S; Stone MD; Moser B; Sewell AK; Turton J; Eberl M
    J Bone Miner Res; 2013 Mar; 28(3):464-71. PubMed ID: 23074158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer.
    Izumi H; Yamasaki A; Takeda K; Kodani M; Touge H; Tanaka N; Yanai M; Ueda Y; Sakamoto T; Nishii-Ito S; Makino H; Yamaguchi K; Igishi T; Shimizu E
    Lung Cancer; 2018 Aug; 122():200-205. PubMed ID: 30032832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
    Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
    J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
    J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
    Hodgins NO; Wang JT; Al-Jamal KT
    Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells.
    Ko Y; Jeong YH; Lee JA
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients.
    Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T
    Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.